期刊文献+

载脂蛋白E及胆固醇酯转运蛋白基因多态性与冠心病的相关研究 被引量:3

Interaction between ApoE and cholesteryl ester transfer protein polymorphism and effects on coronary heart disease
下载PDF
导出
摘要 目的探讨载脂蛋白E(ApoE)基因多态性和胆固醇酯转运蛋白(CETP)基因多态性与冠心病发生风险的关系以及二者有无交互作用。方法筛选冠心病患者121例及非冠心病者107例为研究对象,应用聚合酶链反应限制片长多态性分析方法检测ApoE基因多态性和CETP基因多态性。结果冠心病组ApoE4等位基因频率(10.7%)显著高于对照组(4.7%,P<0.05);CETP基因型频率在两组间差异无统计学意义(P>0.05)。ApoE4是冠心病的独立危险因素(OR=2.502,95%CI1.017-6.156,P=0.046)。CETP基因型及其与ApoE的交互作用与冠心病发生风险无显著性关系(P>0.05)。结论ApoE4基因型与高TC、LDL-C水平有密切关系。冠心病患者ApoE4等位基因频率显著高于对照组。等位基因E4是冠心病的独立危险因素。CETP基因型频率在冠心病组和对照组无显著性差异。CETP基因型及其与ApoE基因型的交互作用对冠心病的发生无显著性影响。 Objective To determine the frequency of the ApoE and cholesteryl ester transfer protein(CETP) polymorphism in Chinese,and to investigate its relationship with plasma lipid levels and coronary heart disease(CHD).Methods In this case-control study,ApoE and CETP-TaqIB polymorphism were examined in 121 patients with CHD and 107 non-CHD controls.Polymerase chain reaction-restricted fragments length polymorphism was used to determine ApoE and CETP genotype.Results ApoE4 allele was significantly more prevalent in CHD patients(10.7%) than in controls(4.7%,P0.05).ApoE4 allele was an independent risk factor for CHD(OR=2.502,95%CI 1.017-6.156,P=0.046).The interaction between ApoE and CETP genotype had no significant effect on CHD.Conclusion It is the first study to explore the effect of interaction between ApoE and CETP genotype and its effect on CHD.ApoE4 allele is an independent risk factor for CHD.The interaction between ApoE and CETP genotype has no significant effect on CHD.
作者 李虎 赵水平
出处 《临床荟萃》 CAS 2009年第24期2127-2130,共4页 Clinical Focus
关键词 冠状动脉疾病 胆固醇酯类 载脂蛋白E 多态性 单核苷酸 coronary arteriosclerosis cholesterol esters apolipoprotein E polymorphism single nucleotide
  • 相关文献

参考文献9

  • 1Rail SC, Weisgraber KH, Mahley RW, et al. Human apolipoprotein E[J]. J Bio Chem, 1982,257(5) :4171- 4178.
  • 2Kuivenhoven JA,Jukema JW,Zwinderman AH,et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis[J].NEngl J Med,1998,338(2)86-93.
  • 3Marshall HW, Morrison I.C, Wu LL, et al. Apolipoprotein E polymorphisms fail to define risk of coronary artery disease.Results of a prospective, angiographically controlled study[J]. Circulation, 1994,89(2) :567- 577.
  • 4Fumeron F,Betoulle D, Luc G, et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction[J]. J Clin Invest, 1995,96(4) : 1664-1671.
  • 5Kark JD, Sinnreich R, I.eitersdorf E, et al. TaqlB CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex difference in a Jewixh population sample characterized by low HDL-cholesterol [J]. Atherosclerosis, 2000, 151 ( 6 ) 509- 518.
  • 6Seuteri A,Bos A J, Zonderman AB, et al. Is the apoE4 allele an independent predictor of coronary events?[J]. Am J Med, 2001,110(1) :28-32,.
  • 7Zak Z, Lagrost L, Gautier T,et al. Expression of simian CETP in normolipidemic Fisher rats has a profound effect on large sized apoE-containing HDL[J]. J Lipid Res, 2002, 43 (12): 2164- 2171.
  • 8Marotti KR, CastLe CK, Boyle TP, et al. Severe atherosclerosis in transgenie mice expressing simian cholesteryl ester transfer protein[J].Clin Chin Acta,2006,231(5):147-160.
  • 9Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al. Plasma levels of Cholesteryl Es2ter Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: the Prospective EPIC ( European Prospective Investigation into Cancer and nutrition )-Norfolk Popu21ationStudy [J].Circulation. 2004,110( 11 ): 1418-1423.

同被引文献42

  • 1张志泉,俞娟,陈连英,于婷,刘才旺,王惠民.高甘油三酯血症患者血清载脂蛋白CⅢ含量分析[J].南通大学学报(医学版),2008,28(1):30-32. 被引量:4
  • 2崔爱庆,刘桂荣.理脾调脂胶囊治疗高三酰甘油血症疗效观察[J].山东中医杂志,2005,24(7):398-399. 被引量:3
  • 3江伟,邱春亿.年龄相关性黄斑变性(AMD)实验模型的研究进展(英文)[J].国际眼科杂志,2007,7(3):585-589. 被引量:5
  • 4刘桂荣 蔡英奇.调脂胶囊治疗血脂失调症的实验研究.中华中西医结合杂志,2002,(10):1-2.
  • 5U.S. National Library of Medicine. Apoe apolipoprotein E [ Rattus nor- vegicus ] [ DB/OL]. http://www, ncbi. nlm. nih. gov/gene/25728.
  • 6Watanabe RM. Drugs, diabetes and pharmacogenomics: the road to personalized therapy[J]. Pharmaeogenomies, 2011, 12 (5) : 699-701.
  • 7Neuvonen PJ. Drug interactions with HMG CoA reductase in- hibitors (statins) : the importance of CYP enzymes, transport- ers and pharmacogenetics[J]. Curr Opin Investig Drugs,2010, 11(3): 323 -332.
  • 8Toda T,Eliasson E. Roles of different CYP enzymes in the for-marion of specific fluvastatin metabolites by human liver microsomes[J]. Basic Clin harmacol Toxicol, 2009, 105 (5) : 327- 332.
  • 9Niemi M, Cascorbi I. Glyburide and glimepiride pharmacoki- netics in subjects with different CYP2C9 genotypes[J]. Clin Pharmacol Ther, 2002, 72 : 326- 332.
  • 10Julia K, Dirk K. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (- )-3S, 5R-fluvastatin and ( + ) 3R, 5S-fluvastatin in healthy volunteers[J]. Clin Pharmacol Ther,2003; 74:186- 94.

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部